ClinicalTrials.gg
RecruitingNCT06910605DS-ADHD1Updated Jun 5, 2025

Exploring Parameters of Driving Simulation in Relation to Drug Holidays in ADHD Patients

An interventional study of "drug holidays" (D) in ADHD - Attention Deficit Disorder With Hyperactivity, Driving Simulator Performance and ADHD, sponsored by Stefan Lakämper. Recruiting at 1 site in Switzerland. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Stefan Lakämper · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland — 5 open to participants now, 6 under way, 1 of them phase 3. Attention Deficit Disorder with Hyperactivity · Switzerland.

Planned enrollment
12th of 14
26 · median 80
Started
2025
with 3 others
No phase
7 of 18
3 open now
Registered
15th of 18
by date

Among the 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland, this one is the 12th largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2025, is one of 7 with no phase, and was the 15th registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

5 of the 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 10 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Attention Deficit Disorder with Hyperactivity with a site in Switzerland, or all of them as a file.
02

Study summary

Attention deficit hyperactivity disorder (ADHD) or syndrome (ADHS) is a symptomatically defined condition that - if untreated - is linked to a significantly increased risk of traffic accidents. In a recent umbrella review, where data from reviews and meta-analyses on 21.142.129 adults was assessed, a pooled prevalence of 3.1% of ADHD in adults was estimated. Considering that globally around 1.35 million people lose their lives and more than 50 million are suffering from injuries or disabilities due to road accidents, the fraction of car accidents caused by ADHD as a risk factor is considerable and needs to be addressed. This risk is largely presumed to be caused by an elevated level of inattentiveness in affected persons.

Compounds of different groups, which can be classified in stimulants - formulations of methylphenidate and amphetamine - and non-stimulants - atomoxetin, guanfacine and clonidine -, have been shown to be effective in alleviating negative effects of ADHD, including inattentiveness. Under well-established but individually managed medication regimes, affected individuals can consequently lead a largely "unirritated" life and are not subject to fundamental restriction with respect to driving anymore.

In children and adolescents, documented negative effects of stimulant medication include loss of appetite and decreased growth rates. It could however be shown that short-term interruptions (weekend, school holidays, and alike), introduced to alleviate aforementioned effects, do not affect the drug's beneficial effects in functional use (e.g., school). Such monitored medication breaks are often called "drug holidays" (D). They have become standard procedure in well-monitored treatment, predominantly including behavioral therapy.

Based on own experience in childhood and or hearsay, also a fraction of affected adults under stimulant medication expresses the desire to take drug holidays and "be themselves" from time to time. With the predominant fraction of medication being fast acting drugs in extended-release formulation and typical patients being not only highly compliant but also extremely informed and adherent, these so-called "drug holidays" are reported an accepted in therapeutically accompanied settings of adults by now.

However, while the overall positive effect of stimulant treatment on driving performance has been confirmed in a row of excellent on road- and/or simulation studies using integrated driving scores (IDS), so far there is no study available addressing the effect of drug holidays in adult drivers on driving performance. This represents a significant gap of evidence for both medical experts and affected.

The proposed study will address this gap by exploring parameters of driving simulation in relation to drug holidays in ADHD patients.

03

Conditions studied

  • ADHD - Attention Deficit Disorder With Hyperactivity
  • Driving Simulator Performance
  • ADHD
  • Driving Behavior
  • Driving Ability

Keywords

  • driving simulation
  • driving performance
  • eye tracking
  • EEG-recording
  • stimulant treatment
  • drug holidays
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult drivers
  • ADHD-diagnosed, established ADHD-treatment only with stimulants
  • known history of drug holidays based on own decision,
  • at impaired eyesight with more than +/- 5 diopter or astigmatism
  • contact lenses are required (for eye tracking)

Exclusion criteria

Exclusion criteria:

  • sensibility to motion sickness (kinetosis, dizziness etc. in 5 min screening drive)
  • non-stimulant-treatment
  • inability to understand the study procedure for linguistic or cognitive reasons
  • professional drivers (if working during the study period)
  • for women: pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Group 1: M-M-D

    stimulant-treated ADHD-affected participants will perform test sequence first in medicated state (M), then again in medicated state (M), then during "drug holidays" (D).

    Drug: "drug holidays" (D)

  • Experimental
    Group 2: M-D-M

    stimulant-treated ADHD-affected participants will perform test sequence first in medicated state (M), then during "drug holidays" (D), then again in medicated state (M).

    Drug: "drug holidays" (D)

Interventions

  • Drug"drug holidays" (D)

    Participants omit three consecutive daily doses of ADHD-medication (stimulant).

06

What researchers measure

Primary outcomes

  1. Significant differences in IDS between conditions D and M

    Primary outcome parameter IDS (Integrated Driving Score) will be calculated by summation of z-scores of typical driving parameters such as, for example, the standard deviation of lane position (SDLP), standard deviation of velocity (SDS) or number of inappropriate lane departures, ILD. IDS will be measured on day 0 (= baseline, Visit 1), on day x (with x≥4, Visit 2) and on day x+3 (Visit 3).

    Time frame: 0, x, x+3 days, with x≥ 4 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Results will be published in peer-reviewed journals. Anonymized raw data will be made available upon request.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: starting after publication of study protcol and/or results

Access criteria: upon request by mail

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 16 months after the start.

Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 16 months is below that.

Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
Apr 4, 2025
StartActual
Jun 2, 2025
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2026
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06910605
Lead sponsor
Stefan Lakämper
Collaborators
Psychiatric University Hospital, Zurich, Swiss Federal Institute of Technology in Zurich (ETHZ)
Responsible party
Stefan Lakämper (Dr. rer. nat. , Head Research & Research Development, Division of TRaffic Medicine, Institute for Forensic Medicine, University of Zurich, University of Zurich) — Sponsor-investigator
First posted
Apr 4, 2025
Start date
Jun 2, 2025
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Jun 5, 2025

Study contacts

Stefan Lakämper, Dr. rer. nat.
Contact
stefan.lakaemper@irm.uzh.ch
+41793789984
Nan Li, MSc
Contact
nan.li@irm.uzh.ch
+41797283245
Stefan Lakämper, Dr. rer. nat.
principal investigator · University of Zurich
Kristina Keller, Dr. med.
principal investigator · University of Zurich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion